Whitehouse Laboratories Announces Development of Container Testing Center - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Whitehouse Laboratories Announces Development of Container Testing Center



Untitled Document

Whitehouse Laboratories announced the expansion of a new laboratory dedicated to container testing. The expansion will include will a 5000 ft2 laboratory for routine container testing and a Container Closure Integrity Test (CCIT) facility. The laboratory is expected to be complete by February 1, 2014.

The laboratory will contain all instruments required to meet the new USP routine testing directives expected in 2014. In addition, the CCIT laboratory will provide method development, validation, and testing services, which include helium flow, vacuum decay, electrical conductivity, laser diffraction, and residual seal force. The facility will also include onsite capping ability and a full-service package distribution laboratory. The laboratory will be under the direction of Brian Mulhall, who has over 20 years of container and package testing experience.

Source: Whitehouse Laboratories

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here